ArticleBMC cancer2025
Predicting breast cancer response to neoadjuvant therapy by integrating radiomic and deep-learning features from early-and-peak phases of DCE-MRI.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Interim Breast MRI for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer.European journal of breast health · 2026Article
- Time-Dependent DCE-MRI Radiomics to Predict Response to Neoadjuvant Therapy in Breast Cancer: A Multicenter Study with External Validation.Diagnostics (Basel, Switzerland) · 2026Article
- Construction and validation of a CT-based radiomics-deep learning signature for non-invasive prediction of PD-L1 expression and immunotherapy outcomes in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review.Frontiers in oncology · 2026Review
- BCMM: gated bidirectional cross-attention fusion of breast MRI and clinical features for predicting RCB response in the I-SPY1 cohort.Frontiers in artificial intelligence · 2026Article
- Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer.Frontiers in immunology · 2026Article
- Radiomics and Deep Learning: Bridging Breast Cancer Imaging Phenotypes and Genomic Heterogeneity.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNon-invasive prediction of pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant therapy (NAT) is crucial for adjusting surgical strategies and optimizing treatment plans. This study aims to develop a predictive model that integrates traditional radiomics and 3D deep learning features from early and peak phases of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pCR after NAT.
methodsThis retrospective study included 234 breast cancer patients from two hospitals who received neoadjuvant therapy. Dataset 1 (n = 204) was used for model development, and Dataset 2 (n = 30) was used for external validation. Traditional radiomics and 3D deep learning features were extracted from both the whole DCE-MRI image and the tumor region of interest (ROI). Features from different sources were integrated, followed by feature selection using independent sample t-tests and least absolute shrinkage and selection operator (LASSO) regression, and the top ten discriminative features were selected for model training. Logistic regression was used to build predictive models, and their performance was evaluated using receiver operating characteristic curves and area under curve (AUC). The DeLong test was used to assess differences between the AUC values of different models, and SHAP (SHapley Additive exPlanations) analysis was employed to examine the relationship between the features of the models and pCR.
resultsFor models using only traditional radiomics features, the combined model integrating early and peak phases of DCE-MRI provided the best pCR prediction. The performance of this combined model was further enhanced by adding 3D deep learning features. The optimal model (RD_EP), which integrated radiomics and deep learning features from early and peak phases of DCE-MRI, achieved AUC values of 0.892 (95% CI: 0.853-0.922) on Dataset 1 and 0.825 (95% CI: 0.713-0.886) on Dataset 2. The DeLong test showed that RD_EP had statistically significant differences compared to other prediction models (p < 0.05). SHAP analysis demonstrated that two radiomics texture features contributed the most to the model.
conclusionIntegrating traditional radiomics and 3D deep learning features from different phases of DCE-MRI can accurately predict pCR to NAT in breast cancer accurately. Multi-phase imaging and diverse features are important to improve predictive accuracy and the constructed model may help guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.